We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

First Blood-Based Biomarkers Test to Predict Treatment Response in Cancer Patients

By LabMedica International staff writers
Posted on 30 May 2023
Print article
Image: Newly observed anti-FSP antibodies have also been found to predict immune-related adverse events (Photo courtesy of Calviri)
Image: Newly observed anti-FSP antibodies have also been found to predict immune-related adverse events (Photo courtesy of Calviri)

Every year worldwide, lung cancer afflicts over two million individuals and almost the same number of people succumb to the disease. This malignancy leads the charts in cancer-related mortalities, with the United States witnessing more deaths from lung cancer than from colon, prostate, and breast cancers combined. Although immune checkpoint inhibitors (ICIs) are commonly used in the treatment of lung cancer, their effectiveness is compromised by low response rates, high costs, and the risk of therapy-induced side effects.

Scientists at Calviri, Inc. (Phoenix, AZ, USA) studying the efficacy of ICI therapies in patients with advanced lung cancer have discovered that anti-frameshift peptide antibodies (anti-FSP antibodies), a new category of blood-based biomarkers, have the potential to be developed into improved or new orthogonal tests for predicting tumor responses to treatment. Interestingly, these antibodies could also be instrumental in predicting immune-related adverse events (irAEs) in patients with lung cancer. As part of their investigation, the scientists evaluated serum samples taken from 74 advanced lung cancer patients prior to their treatment with anti-PD-L1 or anti-PD-1 immunotherapy, with or without concurrent chemotherapy. The presence of antibodies recognizing FSPs was detected on peptide microchips. These biomarkers successfully predicted post-treatment tumor responses and adverse events with a remarkable 90-100% accuracy, using a single test.

Despite its small scale, this study signifies the first significant step towards reliably predicting immunotherapy outcomes, potentially leading to improved patient outcomes. Simple, accurate tests to forecast therapy outcomes could empower doctors to suggest treatments for patients who are most likely to benefit, including those with cancers typically resistant to ICIs. Such a predictive test would also enable the identification of patients requiring close monitoring for potential toxicities, allowing therapy doses to be adjusted or paused if necessary. It might also affect the decision to combine chemotherapy with primary ICI therapy for certain patients, as chemotherapy does not always provide additional benefits over ICIs. Predicting whether it is needed could alter treatment recommendations. Furthermore, the implications of this research extend beyond lung cancer, suggesting that for other cancers like brain cancer—where ICIs have traditionally shown low response rates—a screening test for responsive patients could be a lifesaver.

"In previous studies, other biomarkers have shown some encouraging results for predicting ICI therapy tumor responses. However, extraction and testing are elaborate, often unreliable, and sometimes not possible, and there is no test for predicting adverse events," said Kathryn Sykes, the Vice President of Research and Product Development at Calviri. "Our study explores anti-FSP antibodies as novel biomarkers, which can be simply and accurately measured from a small amount of blood."

"We expect these results will justify the approach and facilitate access to the required larger serum sample cohorts for developing and licensing predictive diagnostics based on this technology," said Stephen Albert Johnston, CEO of Calviri. "Future efforts will focus on improving this approach for addressing specific needs in lung cancer treatment and for evaluating this ICI predictive test platform for other research."

Related Links:
Calviri, Inc. 

Platinum Supplier
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Gold Supplier
ESR Analyzer
Electronic Pipettes Stand
Countertop Platelet Incubator

Print article


Clinical Chemistry

view channel
Image: The new assays are designed to run on the B•R•A•H•M•S KRYPTOR compact PLUS clinical chemistry analyzer (Photo courtesy of Thermo Fisher)

Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia

Preeclampsia is a life-threatening blood pressure condition that can arise during pregnancy and the postpartum phase. This severe pregnancy complication is a primary cause of maternal and fetal mortality... Read more

Molecular Diagnostics

view channel
Image: The ClarityDX Prostate test can reduce unnecessary prostate biopsies by up to 35% (Photo courtesy of Nanostics)

Innovative Blood Test to Revolutionize Prostate Cancer Detection and Reduce Invasive Biopsies

One in six men will receive a prostate cancer diagnosis during their lives. Thankfully, if caught early, prostate cancer is highly treatable. However, the existing screening process has its limitations.... Read more


view channel
Image: The latest FDA clearance has finally brought HemoScreen to its full potential as a true POC hematology analyzer (Photo courtesy of PixCell)

True POC Hematology Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput

An innovative 5-part differential Complete Blood Count (CBC) analyzer with direct capillary sampling capability significantly simplifies blood sampling and minimizes the pre-analytical process.... Read more


view channel
Image: On-chip pretreatment and rapid AST based directly on positive blood cultures (Photo courtesy of Liu Yang)

Integrated Solution for Rapid AST Directly From Positive Blood Cultures to Combat Bloodstream Infection

The presence of living bacteria in the bloodstream, known as bacteremia, can lead to serious conditions like bloodstream infections (BSIs) and sepsis, which can often be fatal. Quickly prescribing the... Read more


view channel
Image: A new microscopy method detects treatment-resistant cancer cells early (Photo courtesy of 123RF)

New Rapid-Live Screening Microscopy Technique Enables Early Detection of Treatment-Resistant Cancer Cells

Chemotherapy serves as an effective tool in the fight against cancer, yet some cancer cells can evade treatment by going into a dormant state known as senescence. These so-called therapy-induced senescent... Read more


view channel
Image: A new electrochemical device can quickly and inexpensively identify people at greatest risk for osteoporosis (Photo courtesy of ACS Central Science, 2023)

Electrochemical Device Identifies People at Higher Risk for Osteoporosis Using Single Blood Drop

With the global increase in life expectancy, the incidence of age-related conditions like osteoporosis is increasing. Osteoporosis, affecting around 200 million individuals worldwide, has a higher incidence... Read more


view channel
Image: AACC Middle East is a two-day conference that brings the latest in laboratory medicine to the Middle East region (Photo courtesy of ADLM)

AACC Middle East 2023 to Explore Latest Trends in Clinical Pathology and Laboratory Medicine

The AACC Middle East Conference and Exposition will be held by the Association for Diagnostics & Laboratory Medicine (ADLM - formerly AACC, Washington, DC, USA) in partnership with Life Dx (Abu Dhabi,... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.